SYDNEY, March 11 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; NASDAQ: PXSL) is pleased to announce that it has appointed Praxis Pharmaceutical France SARL as its French marketer and distributer for the asthma diagnostic tool, Aridol.
Praxis Pharmaceutical is a recently established company created to introduce a portfolio of respiratory specialist products into the French pharmaceutical market. Praxis will complete the reimbursement application for Aridol in France and thereafter market the product to hospital specialists.
Dr Alan Robertson, Pharmaxis CEO said "We are delighted to announce this agreement and are looking forward to working with Praxis on developing the French market for Aridol. Aridol is a precisely engineered test that we believe will be an improvement on current practice. Aridol improves the identification of bronchial hyperresponsiveness which is one of the hallmarks of asthma."
The total population affected by Asthma in France is approximately 3.1 million. The French bronchial challenge testing market is dominated by methacholine and more than 25,000 tests are conducted annually with little recent innovation in the field. Aridol's ability to detect airway hyperresponsiveness in poorly controlled asthmatics offers information to the respiratory physician that has previously not been available.
Aridol is approved for sale in most major European countries, Australia and Korea. Aridol has been included in the Global Initiative for Asthma guidelines, and in the U.S. Asthma Management Guidelines. It is one of the tests recommended by the World Anti-Doping Agency, and other sports governing bodies to ensure elite athletes who are asthmatic are properly diagnosed and treated.
The statements contained in this media r
|SOURCE Pharmaxis Ltd|
Copyright©2009 PR Newswire.
All rights reserved